Although the name suggests the disease affects only the kidneys, development of fluid-filled cysts can spread to the liver, the pancreas, and other organs. While a healthy kidney is about the size of a fist, a kidney filled with cysts from polycystic kidney disease (PKD) can grow to be about the size of a football weigh up to 30 pounds
Regulus Therapeutics announced today FDA has granted the company orphan drug designation for RGLS4326, an investigational therapy being studied to treat autosomal dominant polycystic kidney disease (ADPKD), the most common type of a group of genetic disorders that lead to end-stage renal disease, morbidity, and early death.
ADPKD is caused by mutations in the PKD1 or PDK2 genes. If one parent has the disease, each child has a 50% chance of inheriting it; this form accounts for 90% of the cases.
Other cases are caused by autosomal recessive PKD, when mutations are inherited from both parents who do not have the disease. Both parents must be carrying the mutation but neither may be aware of it. Each child may have a 25% chance of developing PKD.
Although the name suggests the disease affects only the kidneys, development of fluid-filled cysts can spread to the liver, the pancreas, and other organs. While a healthy kidney is about the size of a fist, a kidney filled with cysts from PKD can grow to be about the size of a football weigh up to 30 pounds. Patients with PKD also experience heart valve problems, hypertension, urinary tract infections, colon problems, and significant pain. They can suffer brain aneurysms or strokes. An estimated 500,000 people have PKD.
The investigational therapy, RGLS4326, is a novel oligonucleotide that inhibits miR-17, a microRNA precursor family; the therapy is designed to preferentially target the kidney. Preclinical studies demonstrated an ability to directly regulate PKD1 and PKD2, reducing cyst growth in both human and in vitro ADPKD models. Early work has shown an ability the reduce the spread of cysts and improve kidney function in mice.
Last week, the company announced it had completed a dosing study in healthy volunteers. It is beginning a phase 1b study in patients with ADPKD to study short-term treatment with the study drug to examine safety, tolerability, pharmacokinetics, and changes in disease biomarkers.
The drug’s Investigational New Drug application is on partial clinical hold with FDA, until a second set of requirements have been met.
"This is an important milestone for our APDKD program and our efforts to address the significant unmet medical needs with this disease,” Jay Hagan, CEO of Regulus, said in a statement.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen